Results 71 to 80 of about 53,329 (292)

Tadalafil para o tratamento da hipertensão arterial pulmonar idiopática Tadalafil as treatment for idiopathic pulmonary arterial hypertension

Arquivos Brasileiros de Cardiologia, 2006
O uso de inibidores de fosfodiesterase, mais especificamente o sildenafil, no tratamento da hipertensão arterial pulmonar mostrou bons resultados, indicados por melhora dos parâmetros hemodinâmicos e da capacidade funcional.
Adriana Castro de Carvalho, André Luiz Hovnanian, Caio Julio César dos Santos Fernandes, Mônica Lapa, Carlos Jardim, Rogério Souza   +5 more
doaj   +1 more source

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease

Haematologica, 2020
The most common treatment for patients with sickle cell disease (SCD) is the chemotherapeutic hydroxyurea, a therapy with pleiotropic effects, including increasing fetal hemoglobin (HbF) in red blood cells and reducing adhesion of white blood cells to ...
James G. McArthur, Niels Svenstrup, Chunsheng Chen, Aurelie Fricot, Caroline Carvalho, Julia Nguyen, Phong Nguyen, Anna Parachikova, Fuad Abdulla, Gregory M. Vercellotti, Olivier Hermine, Dave Edwards, Jean-Antoine Ribeil, John D. Belcher, Thiago T. Maciel   +14 more
doaj   +1 more source

The Next Generation of Phosphodiesterase Inhibitors:  Structural Clues to Ligand and Substrate Selectivity of Phosphodiesterases

, 2016
The Next Generation of Phosphodiesterase Inhibitors:  Structural Clues to Ligand and Substrate Selectivity of ...
Richard A. Hughes (1441735), David T. Manallack (1616794), Philip E. Thompson (1374795)   +2 more
core   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury

, 2014
Developing therapeutics for traumatic brain injury remains a challenge for all stages of recovery. The pathological features of traumatic brain injury are diverse, and it remains an obstacle to be able to target the wide range of pathologies that vary ...
Atkins, Coleen M, Oliva, Anthony A, Titus, David J, Wilson, Nicole M   +3 more
core   +1 more source

Development of a Zebrafish Embryo‐Based Test System for Thyroid Hormone System Disruption: 3Rs in Ecotoxicological Research

Environmental Toxicology and Chemistry, EarlyView.
Abstract There is increasing concern regarding pollutants disrupting the vertebrate thyroid hormone (TH) system, which is crucial for development. Thus, identification of TH system–disrupting chemicals (THSDCs) is an important requirement in the Organisation for Economic Co‐operation and Development (OECD) testing framework.
Lisa Gölz, Melanie Blanc‐Legendre, Maximilian Rinderknecht, Laura Behnstedt, Sara Coordes, Luisa Reger, Sacha Sire, Xavier Cousin, Thomas Braunbeck, Lisa Baumann   +9 more
wiley   +1 more source

Evaluation of the Therapeutic Index of a Novel Phosphodiesterase 4B– Selective Inhibitor Over Phosphodiesterase 4D in Mice

Journal of Pharmacological Sciences, 2013
Phosphodiesterase 4 (PDE4) inhibitors have been developed for the treatment of pulmonary inflammatory diseases, but their clinical use was dose-limited by mainly gastric adverse effects.
Osamu Suzuki, Kiyoshi Mizukami, Maki Etori, Yoshitaka Sogawa, Nana Takagi, Hiroshi Tsuchida, Kiyoshi Morimoto, Taiji Goto, Toshiharu Yoshino, Tsuyoshi Mikkaichi, Kazuki Hirahara, Satoshi Nakamura, Hiroaki Maeda   +12 more
doaj   +1 more source

Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review

Pulmonary Circulation, 2020
Pulmonary Hypertension due to left heart disease is the most common type of Pulmonary Hypertension. Morbidity and mortality significantly increase once Pulmonary Hypertension is present.
Galo M. Sanchez Palacios, Cindy Schmidt, Tammy Wichman   +2 more
doaj   +1 more source

Biological and Structural Characterization of Trypanosoma cruzi Phosphodiesterase C and Implications for Design of Parasite Selective Inhibitors

, 2012
Trypanosoma cruzi phosphodiesterase C (TcrPDEC) is a potential new drug target for the treatment of Chagas disease but has not been well studied. This study reports the enzymatic properties of various kinetoplastid PDECs and the crystal structures of the
Chen, Gong, Robinson, Howard, Wang, Huanchen, Seebeck, Thomas, Martinelli, Sibylla, Wan, Yiqian, Ke, Hengming, Wang, H., Wan, Y., Ke, H., Martinelli, S., Kunz, Stefan, Kunz, S., Chen, G., Robinson, H., Seebeck, T.   +15 more
core   +1 more source